Autophagy is an intracellular self-digestion mechanism, by which cellular components are sorted into double-membrane autophagosomes and delivered to lysosomes for degradation. Cells utilize autophagy to dispose of wastes and eliminate hazards, while recycling nutrients and tuning metabolism in the process. Through these functions, autophagy promotes cell fitness, genome integrity, tissue homeostasis, and cell survival and growth under stress. Autophagy up-and down-regulation have both been found in human cancers, suggesting a complex role in tumor development. Accumulating results from autophagy-deficient mice and mouse models of human cancers have demonstrated that autophagy generally suppresses tumor initiation, but promotes tumor progression, in a manner that is dependent on timing and context and modified by specific tumorigenic events. Given the role of autophagy in facilitating tumor growth, autophagy inhibition has gained wide attention as a potential anticancer therapy. Here, we summarize relevant genetic, preclinical and clinical studies and discuss the multifaceted role of autophagy in cancer, as well as the prospects of autophagy inhibition for cancer therapy.
Background

Autophagy as an intracellular self-digestion mechanism
Macroautophagy (autophagy hereafter) is a catabolic process whereby cellular material is enclosed in the double-membrane autophagosomes and delivered to lysosomes for degradation (1) (2) (3) (4) . Autophagy begins with the formation of a crescent-shaped phagophore (or isolation membrane) (Fig. 1 ). This highly regulated process involves 2 key kinases, the UNC-51-like kinase (ULK) and the Class III phosphatidylinositol 3-kinase VPS34, their associated regulatory factors, such as FIP200, Beclin-1, UVRAG and BIF-1, and several other autophagy-related (ATG) proteins (Fig. 1 ). Upon induction, ULK (ATG1) phosphorylates Beclin-1 (ATG6) and activates the VPS34 complex (5).
VPS34 generates phosphatidylinositol 3,4,5-triphosphate (PI3P) on the membrane destined to become a phagophore, and PI3P recruits proteins required for phagophore elongation.
Phagophore elongation requires the incorporation of phosphatidylethanolamine (PE)-lipidated LC3 (ATG8), whose formation is catalyzed by two "ubiquitin-like conjugation systems" composed of multiple other ATG proteins such as ATG5 and ATG7, etc. (2) . The phagophore elongates until its membranes fuse, generating an autophagosome, which eventually fuses with the lysosome forming an autolysosome, where the resident lysosomal hydrolases breakdown the cargo.
Basal autophagy uses adaptor proteins, such as p62/SQSTM1 and NIX, to identify and deliver misfolded or aggregated proteins and damaged organelles to the autophagosome for degradation (6, 7) , thereby preserving cellular fitness. Key to this selective cargo delivery are the specific interactions between the adaptor proteins and the phagophore membrane-bound LC3 (LC3-II), which serves as a cargo receptor
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Author Manuscript Published OnlineFirst on August 27, 2014; DOI: 10.1158/1078-0432.CCR- Under stress conditions, such as oxygen and/or nutrient deprivation, autophagy is induced as a survival mechanism to recycle cytoplasmic constituents and generate fresh nutrients for cellular metabolism, e.g. macromolecule biosynthesis and energy production (8, 9) . Stress-induced autophagy relies on non-selective engulfment of cytoplasmic material by the phagophore for degradation.
Autophagy suppresses oxidative stress and genome instability
Many studies have demonstrated the importance of functional autophagy in limiting oxidative stress (10) (11) (12) (13) (14) . Electron leakage from mitochondrial electron transport to molecular oxygen is a main source of intracellular reactive oxygen species (ROS). As damaged mitochondria are mainly eliminated by autophagy (i.e. mitophagy) (15), autophagy-deficient cells accumulate dysfunctional mitochondria (12, 16) , which are thought to be leaky and produce ROS. In addition, autophagy potentially may also reduce ROS levels by generating reducing powers through its metabolic function or by regulating proteins involved in antioxidant production.
Increased genome instability is a common feature of autophagy-deficient cells (10) (11) (12) . This has been reviewed recently (17) . Since ROS can cause mutations and DNA strand breaks, elevated ROS production in autophagy-deficient cells is considered as a key factor causing genome instability. Autophagy can also promote DNA repair and regulate cell division. During starvation, autophagy via its nutrient recycling function maintains the levels ATP and dNTP (8) , both of which are important for DNA repair.
Moreover, autophagy regulates specific proteins involved in lesion processing and nucleotide production, e.g. Sae2 and Rnr1 (18, 19 yeast causes premature nuclear division in starvation, leading to aneuploidy upon nutrient replenishment (20) .
Autophagy deregulation in human cancers
Autophagy was first linked to cancer when 40%, 50%, and 70% of prostate, breast, and ovarian cancers, respectively, were reported to have allelic loss of BECN1, which encodes the essential VPS34 complex component Beclin-1 (21) . This finding suggests that Beclin-1, and autophagy in general, may be a tumor suppressor. However, recent investigation of BECN1 mutational status in The Cancer Genome Atlas (TCGA) has called into question the significance of allelic BECN1 deletions in cancers (22) , since they occur in conjunction with deletion of the breast and ovarian tumor suppressor gene BRCA1, located only ~150 KB away on chromosome 17q21. Notably, hypermethylation of the BECN1 promoter has been observed in up to 70% of breast cancers (23) , and low BECN1 mRNA levels have been reported in ovarian (24) , colon (25), brain (26) , and liver (27) malignancies. Thus, defective autophagy due to epigenetic silencing and/or transcriptional inhibition of BECN1 may play a role in the etiology and/or progression of these tumors.
Other than BECN1, allelic UVRAG loss is noted in colon (28) and gastric (29) cancers; whereas LAPTM4B, which maintains lysosomal pH and allows autophagosome-lysosome fusion, is frequently amplified and overexpressed in breast cancer (30) . Furthermore, cancers often exhibit functional suppression of autophagy, especially upon activation of the PI3K-AKT-mTOR pathway, which inhibits autophagy (31) . For example, approximately 25% of breast cancers have amplification of HER2 (ERBB2), which encodes a receptor tyrosine kinase that activates the above pathway. (10, 13) . Also, EGFR-and AKT-mediated Beclin-1 phosphorylation, which both attenuate autophagy, promote the growth of lung and breast cancer xenografts, respectively (37, 38) .
Genetic modulation of autophagy in mouse tumor models
Complete or partial autophagy deficiency has been introduced into several mouse tumor models ( Table 1) Author Manuscript Published OnlineFirst on August 27, 2014; DOI: 10.1158/1078-0432.CCR- demonstrate that the role of autophagy in lymphoma depends on the specific drivers of tumor development.
The role of autophagy has also been assessed in multiple breast cancer models.
In the polyoma middle T-antigen (MMTV-PyMT) driven model, conditional biallelic RAS-mutant pancreatic cancer cells have high basal autophagy and seem to be "addicted" to autophagy for growth (47) . Recently, the role of autophagy in pancreatic ductal adenocarcinoma (PDAC) has been thoroughly assessed in a KRAS G12D -driven model in two separate studies (48, 49) . Normally, these mice develop a small number of pre-malignant pancreatic intraepithelial neoplasia (PanIN) lesions, which stochastically evolve into PDAC over time. Interestingly, conditional biallelic deletion of either Atg5 or Atg7 led to increased incidence of PanIN, but blocked its progression to high-grade hyperplasia and PDAC (48, 49) , reminiscent of the effect produced by Atg7 or Atg5 deletion in the above BRAF-and KRAS-driven lung cancer models, respectively.
Besides the timing-, context-and dosage-dependent role of autophagy in tumor development, the above studies also reveal p53 status as a key parameter impacting the role of autophagy in cancer. Specifically, Becn1 haploinsufficiency delayed Palb2-associated mammary tumorigenesis in Trp53-wild type mice, but not when Trp53 was co-deleted with Palb2 in the mammary epithelium (41) . Similarly, co-deletion of Trp53 diminished or eliminated the inhibitory effect of either Atg5 or Atg7 deletion on tumor progression in both KRAS-and BRAF-driven lung cancer models (43) (44) (45) . These results indicate that a key function of autophagy may be to limit p53 induction and/or overcome the barrier imposed by p53 activation to tumorigenesis, and they also suggest that (58), respectively. This strategy has seen promise in preclinical studies and is currently under clinical investigation. However, it should be noted that there exists evidence that suggests that therapy-induced autophagy may contribute to cell killing (56, 57) . Thus, the role of autophagy in cancer therapy needs to be determined case by case in different cancer-drug combinations. (60) . In a phase I study combining the HDAC inhibitor vorinistat with escalating doses of HCQ in patients with advanced solid tumors, the MTD for HCQ was again 600 mg daily; although treatment-related changes in AV numbers in PBMCs were not seen, increases in the expression of CDKN1A and CTSD were reported and were more pronounced in tumor biopsies than PBMCs; out of 24 evaluable patients, 1 patient with renal cell carcinoma (RCC) had confirmed durable PR and 2 patients with colorectal cancer have prolonged stable disease (SD) (61) . In a phase I trial combining bortezomib and HCQ for relapsed/refractory myeloma, PR, minor response and SD were observed in 14%, 14% and 45% of patients, respectively (62) . In this study, HCQ was given at 600 mg twice daily with standard doses of bortezomib and resulted in therapy-associated AV number increases in bone marrow plasma cells. In another phase I study, combination of HCQ with dose-intense temozolomide resulted in 14% PR and 27% SD in patients with metastatic melanoma and induced significant AV accumulation in PBMCs; the recommended phase II dose was HCQ 600 mg twice daily (63) . Finally, combined MTOR and autophagy inhibition in a phase I/II trial of HCQ and temsirolimus resulted in SD in about 70% of patients with melanoma; the HCQ dose in the phase II part of the study was 600 mg twice daily and at that, but not lower, dose, autophagy inhibition was documented in PMBCs and tumor biopsies (64) .
Taken together, the results of the above studies indicate that, when tolerated, the combination of HCQ at higher dose (600 mg twice daily) with standard chemotherapy regimens modulates autophagy in patients and has antitumor activity. Treatment-related toxicities limit the use of high-dose HCQ in combination with vorinostat and during adjuvant chemoradiotherapy for newly resected GBM, thus indicating a need for the development of lower toxicity compounds that inhibit autophagy more consistently than HCQ.
CONCLUSIONS AND PERSPECTIVES
The role of autophagy in cancer is complex and varies depending on the timing and context of tumor development. Yet, despite the seemingly paradoxical roles of autophagy under different settings, two principles have been emerging from the mouse models studied so far. First, basal autophagy generally suppresses tumor initiation. This may be achieved by suppressing ROS, which causes DNA damage and genome instability, thereby promoting age-associated, spontaneous tumor development, as seen in autophagy deficient mice. Also, modestly increased ROS can directly stimulate cell considerable metabolic stress are more likely reliant on autophagy for survival and growth, and should thus be more sensitive to drugs that inhibit autophagy, a set of effective biomarkers to diagnose these autophagy-addicted malignancies may be useful. Also, given the context-dependent tumor-suppressive function of autophagy, the long-term consequences of chronic or periodic pharmacologic autophagy inhibition need to be determined. In the same vein, it is imperative to develop novel agents that specifically target mechanisms upregulating autophagy in cancer cells, while leaving basal autophagy in normal cells intact. 
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